Chk1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in small cell lung cancer by promoting mitotic cell death

INTRODUCTION: Platinum-based chemotherapy remains the standard treatment for patients with small cell lung cancer (SCLC), but the benefit of the treatment is often hampered by rapid development of drug resistance. Thus far, there is no targeted therapy available for SCLC. Over 90% of SCLC tumors har...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Thorac Oncol
Autors principals: Hsu, Wei-Hsun, Zhao, Xiaoliang, Zhu, Jianquan, Kim, In-Kyu, Rao, Guanhua, McCutcheon, Justine, Hsu, Shuo-Tse, Teicher, Beverly, Kallakury, Bhaskar, Dowlati, Afshin, Zhang, Yu-Wen, Giaccone, Giuseppe
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6534433/
https://ncbi.nlm.nih.gov/pubmed/30771522
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2019.01.028
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars